Search Within

Helena Alexandra Yu

Formats
  1. Meeting Abstract (162)
  2. Journal Article (109)
  3. Editorial (9)
  4. Review (7)
  5. Book Section (2)
  6. Correspondence (2)
  7. Conference Paper (1)
Groups
  1. Department of Medicine (292)
  2. Solid Tumor Oncology Division (292)
  3. Thoracic Oncology (292)
  4. GSK Faculty (121)
  5. Department of Pathology and Laboratory Medicine (105)
  6. Human Oncology and Pathogenesis Program (102)

More Groups

People
  1. Gregory Riely (108)
  2. Mark Kris (95)
  3. Marc Ladanyi (71)
  4. Charles Rudin (58)
  5. Maria Arcila (56)
  6. Alexander Drilon (36)

More People

Years
  1. 2025 (21)
  2. 2024 (28)
  3. 2023 (30)
  4. 2022 (33)
  5. 2021 (30)
  6. 2020 (15)

More Years

Publications
  1. Journal of Clinical Oncology (75)
  2. Journal of Thoracic Oncology (63)
  3. Annals of Oncology (27)
  4. Clinical Cancer Research (18)
  5. International Journal of Radiation Oncology, Biology, Physics (14)
  6. Cancer Discovery (9)

More Publications

Publishers
  1. Elsevier Inc. (86)
  2. American Society of Clinical Oncology (85)
  3. American Association for Cancer Research (31)
  4. Oxford University Press (31)
  5. Nature Publishing Group (12)
  6. Elsevier Science, Inc. (7)

More Publishers

Results (292)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers
    Meeting Abstract

    Schoenfeld, A. J.; Chan, J. M.; Rizvi, H.; Rekhtman, N.; Daneshbod, Y.; Kubota, D.; Chang, J. C.; Arcila, M. E.; Ladanyi, M.; Somwar, R.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC
    Meeting Abstract

    Janne, P. A.; Yu, H. A.; Johnson, M. L.; Steuer, C. E.; Vigliotti, M.; Iacobucci, C.; Chen, S.; Yu, C.; Sellami, D. B.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • TATTON phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
    Meeting Abstract

    Yu, H.; Ahn, M. J.; Kim, S. W.; Cho, B. C.; Sequist, L.; Orlov, S.; Ottesen, L. H.; Verheijen, R. B.; Mellemgaard, A.; Wessen, J.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • TATTON phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
    Meeting Abstract

    Sequist, L. V.; Lee, J. S.; Han, J. Y.; Su, W. C.; Yang, J. C. H.; Yu, H.; Ottesen, L. H.; Verheijen, R. B.; Mellemgaard, A.; Wessen, J.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the phase Ib TATTON study
    Meeting Abstract

    Ramalingam, S. S.; Saka, H.; Ahn, M. J.; Yu, H.; Horn, L.; Hida, T.; Cantarini, M.; Verheijen, R.; Wessen, J.; Oxnard, G.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • A novel acquired exon 20 EGFR M766Q mutation in lung adenocarcinoma mediates osimertinib resistance but is sensitive to neratinib and poziotinib
    Journal Article

    Castellano, G. M.; Aisner, J.; Burley, S. K.; Vallat, B.; Yu, H. A.; Pine, S. R.; Ganesan, S.
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Patterns of failure in stage IV non-small cell lung cancer patients treated with osimertinib
    Meeting Abstract

    Peoples, C.; Wang, C.; Yu, H.; Yang, T. J.; Rimner, A.; Wu, A. J.
    International Journal of Radiation Oncology, Biology, Physics (2019)

    Fulltext@MSK | Save
  • Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
    Journal Article

    Schoenfeld, A. J.; Arbour, K. C.; Rizvi, H.; Iqbal, A. N.; Gadgeel, S. M.; Girshman, J.; Kris, M. G.; Riely, G. J.; Yu, H. A.; Hellmann, M. D.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes
    Journal Article

    Offin, M.; Chan, J. M.; Tenet, M.; Rizvi, H. A.; Shen, R.; Riely, G. J.; Rekhtman, N.; Daneshbod, Y.; Quintanal-Villalonga, A.; Penson, A.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • A prospective study of circulating tumor DNA to guide matched targeted therapy in lung cancers
    Journal Article

    Sabari, J. K.; Offin, M.; Stephens, D.; Ni, A.; Lee, A.; Pavlakis, N.; Clarke, S.; Diakos, C. I.; Datta, S.; Tandon, N.; more...
    JNCI: Journal of the National Cancer Institute (2019)

    Fulltext@MSK | Save